Self-Monitoring Blood Glucose (SMBG) Devices Global Market Report 2024

A Self-Monitoring Blood Glucose (SMBG) device is a portable instrument designed to identify potential diabetes indicators. Typically, these devices assess glucose levels by extracting a small blood drop from patients through a finger prick. International guidelines recommend this method for effectively managing diabetes in patients. SMBG devices are instrumental in measuring the concentration of glucose in the blood.

The primary types of Self-Monitoring Blood Glucose (SMBG) devices include self-monitoring blood glucose meters, continuous glucose monitors, testing strips, and lancets. Self-monitoring blood glucose meters are handheld devices utilized by patients at home to monitor their blood glucose levels. These meters typically require a blood drop obtained through a pinprick. They are distributed through hospital pharmacies, retail pharmacies, online sales, and diabetes clinics and centers. These devices find application in various contexts such as Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes.

The self-monitoring blood glucose (SMBG) devices market research report is one of a series of new reports that provides self-monitoring blood glucose (SMBG) devices market statistics, including self-monitoring blood glucose (SMBG) devices industry global market size, regional shares, competitors with a self-monitoring blood glucose (SMBG) devices market share, detailed self-monitoring blood glucose (SMBG) devices market segments, market trends and opportunities, and any further data you may need to thrive in the self-monitoring blood glucose (SMBG) devices industry. This self-monitoring blood glucose (SMBG) devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The self-monitoring blood glucose (smbg) devices market size has grown strongly in recent years. It will grow from $14.35 billion in 2023 to $15.71 billion in 2024 at a compound annual growth rate (CAGR) of 9.5%. The growth observed in the historical period can be attributed to several factors, including an increase in the prevalence of diabetes, a heightened awareness of healthcare, an aging population, government initiatives and regulations, as well as a rise in healthcare spending.

The self-monitoring blood glucose (smbg) devices market size is expected to see strong growth in the next few years. It will grow to $22.15 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The anticipated growth in the forecast period can be attributed to the increasing prominence of home healthcare, the expansion of telehealth services, a rise in disposable income, growing demand for remote monitoring, and an upsurge in e-commerce. Noteworthy trends expected in the forecast period encompass the integration of continuous glucose monitoring (CGM), the utilization of artificial intelligence (AI) and machine learning, the development of wearable self-monitoring blood glucose (SMBG) devices, the advancement of non-invasive monitoring techniques, and the widespread use of mobile apps and connectivity.

The anticipated growth in the self-monitoring blood glucose device market is driven by the increasing prevalence of diabetes. Self-monitoring of blood glucose involves individuals with diabetes using a glycemic reading device, such as a glucose meter, to measure their blood sugar. This method allows individuals to assess the effectiveness of their treatment, including factors like diet, exercise, insulin, and antidiabetic medications. For instance, as reported by the International Diabetes Federation in December 2021, the global adult diabetes prevalence reached 537 million in 2021, with projections indicating an increase to 643 million by 2030 and a staggering 783 million by 2045. Thus, the upward trajectory in diabetes cases is a key factor propelling the growth of the self-monitoring blood glucose devices market.

Another contributing factor to the growth of the self-monitoring blood glucose devices market is the rising geriatric population. This demographic, typically aged 65 and older, experiences age-related physical and cognitive changes, making effective diabetes management crucial. Self-monitoring blood glucose devices play a vital role in helping elderly individuals manage diabetes by facilitating timely adjustments to medication and lifestyle choices. As per the World Health Organization's October 2022 report, the global population aged 60 or older is expected to reach 2.1 billion by 2050, highlighting the increasing significance of catering to the healthcare needs of the elderly. Consequently, the growing geriatric population is a driving force behind the expansion of the self-monitoring blood glucose devices market.

A prominent trend in the self-monitoring blood glucose devices market is technological advancement. Leading companies in this market are actively engaged in developing cutting-edge products to enhance their market presence. For example, Know Labs Inc., a US-based company specializing in glucose monitoring devices, introduced the KnowU, a portable medical-grade glucose monitoring device leveraging Bio-RFID technology. This non-invasive device offers an affordable and convenient alternative to traditional, more invasive blood glucose monitoring devices, providing users with on-the-go monitoring capabilities.

The major players in the self-monitoring blood glucose devices market are increasingly focusing on sensor-based glucose monitoring devices to gain a competitive edge. These medical tools continuously or intermittently measure and report blood glucose levels, aiding individuals with diabetes in managing their condition effectively. In September 2022, Abbott Laboratories received approval from the USFDA for FreeStyle Libre 2 and FreeStyle Libre 3 sensors, allowing integration with Automated Insulin Delivery Systems (AIDs). This approval signifies a significant step toward enhancing diabetes care by automating insulin adjustments based on real-time glucose data from the sensors.

In September 2021, Biocorp, a France-based manufacturer of medical devices, including blood glucose monitoring, partnered with Novo Nordisk for the development and distribution of the Mallya smart add-on device. This device, designed for Novo Nordisk's FlexTouch pen, aims to provide innovative solutions for individuals with diabetes. Novo Nordisk, a Denmark-based healthcare company, brings its expertise to this collaboration, reinforcing the commitment to delivering effective diabetes management solutions.

Major companies operating in the self-monitoring blood glucose (smbg) devices market include Abbott Laboratories, Bionime Corporation, B. Braun Melsungen AG, F. Hoffmann-La Roche Ltd., LifeScan Inc., PHC Holdings Corporation, Home Diagnostics Inc., Terumo Pharmaceutical Solutions, ARKRAY Inc., Ypsomed Holding AG, Dexcom Inc., Medtronic PLC, Novo Nordisk A/S, Glysens Incorporated, Senseonics Holdings Inc., AgaMatrix Inc., All Medicus Co. Ltd., Ascensia Diabetes Care Holdings AG, Bayer AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., Bioptik Technology Inc., Cnoga Medical Ltd., ForaCare Inc., Glucovation Inc., Hainice Medical Inc., Infopia Co. Ltd., Insulet Corporation, Integrity Applications, Johnson & Johnson, Menarini Diagnostics, Nemaura Medical Inc., Nipro Corporation, Nova Biomedical Corporation, Omron Healthcare Inc., Optiscan Biomedical Corporation, OrSense Ltd., Pinnacle Technology Inc., Prodigy Diabetes Care LLC, PTS Diagnostics, TaiDoc Technology Corporation, Trividia Health Inc., WaveForm Technologies Inc.

North America was the largest region in the self-monitoring blood glucose (SMBG) devices market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this self-monitoring blood glucose (SMBG) devices market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the self-monitoring blood glucose (SMBG) devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The self-monitoring blood glucose (SMBG) device market consists of sales of devices and instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.